Anti-proliferative effect of ZnO NPs against the growth of Ehrlich Solid carcinoma

Lamees Dawood, *Ehab Tousson, Afaf El-Atrash, Amira Salama

1Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt
2Department of Zoology, Faculty of Science, Tanta University, Tanta 31527, Egypt
*Corresponding author: ehabitousson@science.tanta.edu.eg
ORCID ID: 0000-0001-9722-3603
DOI: 10.21608/jmals.2019.180380

Abstract

**Background:** Zinc oxide nanoparticle (ZnO NPs) has been widely used in biomedical applications and cancer therapy and has been reported to induce a selective cytotoxic effect on cancer cell proliferation.

**Methods:** Female Swiss Albino mice were inoculated subcutaneously with Ehrlich ascites carcinoma (EAC) cells. ZnO NPs or MTX were injected intraperitoneally. Tumor growth inhibition rate (TIR %), increase in life span (ILS %), zinc concentration, lipid peroxidation marker (MDA), glutathione (GSH) contents, and the activity of the antioxidant scavenger enzymes SOD and catalase CAT was examined. Also, DNA fragmentation and histopathological studies of all groups were carried out. **Results:** Treatment of tumor-bearing mice with ZnO NPs significantly increased (MST), (TIR %), (ILS %) and reduced tumor weight, compared to tumor-bearing controls. Additionally, Zn concentration and DNA fragmentation were significantly increased in tumor tissues. ZnO nanoparticles were also found to induce oxidative stress, evidenced by the generation of reactive oxygen species and depletion of the antioxidants in tumor tissues, with no changes in the liver. Our data demonstrate that ZnO NPs exert distinct effects via the killing of cancer cells. **Conclusion:** The study findings demonstrated that the ZnO NPs can induce selective cytotoxicity through reactive oxygen species generation and oxidative stress.

**Keywords:** Zinc oxide nanoparticles, Methotrexate, Ehrlich solid tumor, selective cytotoxicity, zinc concentration, oxidative stress, DNA fragmentation.

1. **Introduction**

Cancer is a condition of uncontrolled cell differentiation, which has been treated by several modalities, including chemotherapy, radiation, and surgery, during the past several decades.[1,2] Current anticancer chemotherapies based on alkylating agents, antimetabolites, biological agents and natural products frequently fail to produce a complete anticancer response owing to the development of drug resistance or their failure to differentiate effectively between cancerous and normal cells.[3-7] This indiscriminate action frequently leads to systemic toxicity and debilitating adverse effects in normal body tissues, including bone marrow function suppression, neurotoxicity, and cardiomyopathy, which greatly limits the maximal allowable dose of the chemotherapeutic drug.[8] Nanoparticles have been known as a promising agent for cell imaging, biosensing, gene delivery, and cancer therapy. Metal oxide nanoparticles (NPs) such as zinc oxide nanoparticles (ZnO NPs) have been used in biomedical applications and various therapy.[9] The manipulation of ZnO at the nanoscale levels enables precision engineering to control the physicochemical properties of nanoparticles and their interactions with cellular systems.[10] ZnO has been widely used in.
cosmetic lotions and increases anti-bacterial activity.\textsuperscript{[11, 12]} It is also utilized in the cotton fabric, rubber, and food packaging industry.\textsuperscript{[13]}

Zinc oxide nanoparticles have attracted researchers for their implications in cancer therapy and have been reported to induce cytotoxicity at in vitro and in vivo Levels.\textsuperscript{[14]} ZnO NPs have been found to have the potential for use in biomedical and cancer applications due to the attractive chemical properties of these nanomaterials.\textsuperscript{[15]} Previous studies reported that ZnO NPs exhibit a high degree of cancer cell selectivity with the ability to surpass the therapeutic indices, compared to chemotherapeutic agents.\textsuperscript{[16]} ZnO NPs able to preferentially target rapidly dividing cancerous cells, which could serve as a foundation for developing novel cancer therapeutics. ZnO NPs show enhanced cytotoxicity by a generation of reactive oxygen species (ROS), leading to oxidative stress and eventually cell death when the antioxidative capacity of the cell is exceeded.\textsuperscript{[15]} ROS are oxygen metabolites that are highly active in terms of oxidative modifications of cellular macromolecules including proteins, lipids, and polynucleotides.\textsuperscript{[17]} The cellular redox homeostasis is maintained by the balance between ROS production and the antioxidant system in the cell; when ROS is produced excessively or endogenous antioxidant capacity is diminished, indiscriminate oxidation elicits harmful effects, resulting in “oxidative stress”. Several studies proved that excessive oxidative stress is harmful to the cell and causes severe cytotoxicity.\textsuperscript{[17-19]} Upon exposure to oxidants or oxidative stress-inducing agents, a common adaptive response induced in mammalian cells is the upregulation of stress-response genes, many of which encode antioxidant defense enzymes.\textsuperscript{[20-22]} While high levels of ROS production may lead to the induction of apoptosis or necrosis, increasing evidence demonstrates that low or transient ROS exposure increases cell proliferation, likely through altered expression of growth factors and proto-oncogenes\textsuperscript{[23,24]} Experimental tumors have great importance for modeling, and one of the commonest is the Ehrlich solid tumor was chosen as the experimental model of carcinogenesis.\textsuperscript{[25]} It is a neoplasm of epithelial origin, corresponding to murine mammary adenocarcinoma. This tumor is easily cultivated and transferred in vivo and can be used to study the mechanisms of carcinogenesis and evaluate the effect of new therapeutic approaches for tumors.\textsuperscript{[25]} The present study was aimed to investigate the selective toxicity of ZnO NPs against Ehrlich solid carcinoma in mice.

2. Materials and methods

2.1. Materials

Zinc oxide nanoparticles (ZnO NPs) with a diameter of 20-50 nm were purchased from Sigma–Aldrich Company Ltd. The purities of ZnO NPs was 99.5 wt. %. The particular surface areas of ZnO NPs were 50m²/g. This physicochemical information was provided by the manufacturer. Methotrexate (MTX) was purchased from Sanofi (Cairo, Egypt). All different reagents and chemicals employed in this study were purchased from Bio- Diagnostic Medical Company (Egypt).

2.2. Animals

In total, 115 Albino, female mice individually weighing around 20–25 g were housed in wire mesh cages in a constant environment [temperature (23°C± 2°C), relative humidity (80% ± 5%), and light (12 h light/dark cycles)]. They were given ad lib access to a standard diet and water. All experiments were performed following guidelines for animal studies issued by the Ethical Committee of Faculty of Science and Faculty of Medicine, Tanta University, as approved by the Institutional Animal Care and Use Committee (IACUC-SCI-TU-0041).

2.3. Ehrlich Ascites Carcinoma (EAC) Cells and Tumor Inoculation

Murine Ehrlich Ascitis Carcinoma bearing mouse was obtained from National Cancer Institute, Cairo University (Giza, Egypt). Mice were implanted with 0.2 ml of Ehrlich tumor cell suspension (containing about 2×10⁶ viable cells) injected subcutaneously to the right hind limb of the mice for the experiment on day 0.

2.4. Animal treatments

Mice were randomly divided into the following groups:

- **Control (healthy) group [control]** injected intraperitoneally by 200 mL saline (n = 15)
- ZnO NPs control group [ZN] contained normal mice injected intraperitoneally by ZnO NPs (10 mg/kg, once daily for 3 weeks) (n = 25)
- Ehrlich control group [E] included mice subcutaneously implanted by Ehrlich tumor cells (n = 25).
- ZnO NPs -treated group [E + ZN] contained mice injected intraperitoneally by ZnO NPs (10 mg/kg, once daily for 3 weeks)\textsuperscript{[26]} administered 7 days after subcutaneous implantation of Ehrlich tumor cells (n = 25).
- MTX-treated group [E + MTX] contained mice injected intraperitoneally by MTX (1.25 mg/kg, every 48 hours for 2 weeks) administered 7 days after subcutaneous implantation of Ehrlich tumor cells (n = 25).

At the end of the experiment, animals were examined for body weight changes (BW):
(initial BW on day 0, last and net final BWs). Net final BW = (final BW – tumor weight).

BW gain was determined as body weight gain (final BW– initial BW/ initial BW) x100.

2.5. Sample preparation

One month after tumor inoculation, 15 mice from each group were anesthetized by decapitation under ether anesthesia and sacrificed to (1) evaluate the anti-tumor activity of ZnO NPs and (2) conduct a biochemical and histopathological assay. Livers were immediately removed from mice (n = 15/ group), weighed, and sliced into two parts. Ehrlich tumors were carefully removed from the right thigh. Solid tumors were excised for tumor weight determination, longest and shortest diameters of the tumor were measured with the help of a vernier caliper. Tumor volumes were calculated by the following: Tumor volume (mm³) = (length x width²)/2, where the length and width are given in mm.[27]

Tumor tissues were then washed with ice-cold saline three times then chilled on ice. Tumors were divided into two sections, one was kept in 10% neutral buffer formalin for the histopathological examination, and the second was wrapped in aluminum foil, and stored at −20°C till used for measuring zinc content and biochemical assay.[28]

2.6. Calculation of MST and percentage of ILS, T/C, and TIR

The remaining mice (n = 10 mice/group) were kept alive to estimate the mean survival time (MST) and percent increase in life span (% ILS). MST of each group was monitored by recording the mortality daily. The endpoint of the experiment was determined by the spontaneous death of animals and MST was calculated according to the equation: MST = (day of first death + day of last death)/2. The percentage of ILS was calculated using an equation of (ILS% = (T – C)/C × 100), where T represents MST of treated animals and C represents MST of [E] group. T/C% (treated vs. ESC control [E]) was calculated as MST of treated animals/MST of [E] group. TIR% (tumor-growth inhibition rate) = (C – T)/C × 100, where T represents the mean tumor volume of the treated group and C represents the mean tumor volume of the ESC control [E] group.[29] According to the criteria of the National Cancer Institute (NCI), T/C exceeding 125% and ILS exceeding 25% indicate that the drug has significant anti-tumor activity.[30]

2.7. Measurement of zinc content in liver and ESC using ICP-OES

Tumor/mammary glands and liver samples weighing 0.5 gm. were prepared for quantitative estimation of their zinc concentration using inductively coupled plasma optical emission spectrometry ICP-OES (Thermo Scientific iCAP 7000). 0.5 gm of tumor tissue samples were digested in a microwave oven digestive system with HNO₃ (65%) and H₂O₂ (30%) in Teflon vessels. The residues were filtered through 0.45μm Whatman filter paper and transferred to a 50 mL volumetric flask and diluted to 50 mL with deionized water then analyzed for zinc content (analytical wavelength chosen was 213.857 nm). The amount of zinc was calculated from the linear portion of the generated standard curve.[31]

2.8. DNA extraction and fragmentation analysis

The genomic DNA was extracted from the mammary gland and tumor tissue samples using Gene JET genomic DNA extraction kit following the manufacturer’s protocol (Fermentas, #K0721, European Union). Followed by, agarose gel electrophoresis (2%) to detect DNA fragmentation according to Abd Eldaim et al.[32] The fragment patterns (ladder, smear, or intact) were visualized on the UV Trans-illuminator and photographed by a gel documentation system (UVDI Major Science, USA). All samples were processed at one time, to avoid variations due to the extraction method itself.

2.9. Determining oxidative stress biomarkers

Tumor/mammary gland and liver were soaked in PBS (pH 7.4) containing 0.16 mg/ml heparin to remove any red blood cells and clots, and then it was homogenized in 5 ml cold buffer (50 mM potassium phosphate, pH 7.5). The homogenate was then centrifuged at 4,000 rpm for 15 minutes, and the supernatant was carefully collected. To determine the malondialdehyde (MDA) component, a noxious product of lipid peroxidation was detected according to the following: lipid peroxidation was evaluated based on MDA level. MDA was determined using the method as previously described by El Atrash et al.[33] Assay of catalase enzyme activity (CAT; EC 1.11.1.6) was measured by monitoring the decomposition of H₂O₂ (the substrate of the enzyme) at 240nm according to the method described by Salama et al.[34] Assay of superoxide dismutase enzyme activity (SOD; EC 1.15.1.1) in liver homogenate was assayed by the method of Habig et al.[35] Assay of reduced glutathione (GSH) content determination is based on the reduction of 5,5-dithio-bis-(2-nitrobenzoic acid), and it was determined by the colorimetric method according to Barakat et al.[36]

2.10. Statistical analysis

The data are expressed as the mean ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) was used to assess significant differences among treated groups and control. The
Tukey test was used to compare all groups with each other and showed the significant effect of treatment. The criterion for statistical significance was set at* means p ≤ 0.05, (Graph Pad Prism Software).

3. Results

3.1. Animal observation and anti-tumor effects of ZnO-NPs against ESC

To evaluate the anti-tumor effects of ZnO-NPs against ESC, changes in body weight, tumor volume, tumor-growth inhibition rate (TIR %), mean survival time (MST), an increase in life span (ILS %) of treated groups were observed [Table 1]. No toxic signs or mortality were observed related to ZnO-NPs administration in contrast to MTX. Moreover, administration of ZnO-NPs led to a significant decrease (p<0.001) in tumor volume and weight in comparison with ESC mice. On the other hand, treatment of mice (n = 10/group) with ZnO-NPs or MTX significantly increased ILS% with a rate of 111.66% (P < 0.001) and 55.3% (P < 0.01), respectively, as compared to non-treated ESC mice. Similar treatments led to a notable increase in MST with 75.5 (P < 0.001), and 55.6 (P < 0.01) days, respectively, as compared to non-treated ESC mice (35 days). The Tumor-growth inhibition rate (TIR %) of the Ehrlich tumor was found to be 68.8% for ZnO NPs -treated animals and 41.6% for MTX-treated mice.

In a solid tumor, the average tumor volume in [E] mice increased from 111.83±28.91 mm³ to 165±5.3 mm³ after 21 days. In MTX treated group the average tumor volume was observed to increase from 105.01±10.4 mm³ to 976 ± 3.1 mm³. In ZnO NPs treated group the average tumor volume was observed to increase from 108.1±20.14 mm³ to 516±4.14 mm³, indicating the proliferation rate of tumor cells in treated mice was inhibited by ZnO NPs due to a decrease in tumor burden [Figure 1]. The body weight changes were significantly higher in ZnO NPs treated group significantly (P<0.0001) increased 1.7 fold more than the control indicating the effect of ZnO NPs in preventing tumor growth.

3.2. Zn content analysis

A significant (P < 0.0001) increase in the Zn content was found in the tumor of mice treated with ZnO nanoparticles [E + ZN] as compared to the mammary gland of ZnO-NPs control group [ZN] and other groups. In contrast, there was no significant difference in Zn content in the liver of treated groups [ZN] and [E + ZN] and control mice. The liver showed a slight increase in the Zn content but it was not statistically significant [Figure 2].

3.3. Effect of ZnO-NPs on DNA fragmentation

DNA isolated from Ehrlich solid tumor in [E] group and liver tissue of [E + ZN] group showed intact (non-degraded) bands near gel wells. In contrast, a variable degree of DNA fragmentation, revealed by DNA laddering and smearing, was noticed after the administration of ZnO-NPs or MTX. The most severe pattern of DNA fragmentation was observed in ESC mice treated with ZnO-NPs. Liver tissue of [E + MTX] group showed noticed DNA laddering [Figure 3].

3.4. Oxidative stress markers

3.4.1. Effects of ZnO-NPs upon Markers of Oxidative Stress in ESC tissue

It has been suggested that oxidant generation and antioxidant depletion are the common pathways through which anticancer drugs trigger apoptosis in cancer cells.[37] Therefore, the status of oxidants and antioxidants was examined in ESC treated with ZnO NPs or MTX. MDA levels were measured as markers of oxidants, whereas antioxidant status was examined by determining the SOD, CAT, and GSH. Results showed that the levels of SOD, CAT, and GSH were significantly decreased (P < 0.01), MDA were increased (P < 0.01) in tumor tissue of the ESC control group as compared to the mammary gland of the normal group. Figure (4) reveals that MTX - induced toxicity; depletion in the levels of CAT, GSH, and SOD; (P < 0.01), and a significant increase (P < 0.01) in the level of MDA in tumor tissue were detected. Treatment of the Ehrlich solid tumor with ZnO NPs revealed the most significant decrease (P < 0.001) in the levels of CAT, GSH, and SOD and high significance (P < 0.001) increase in the level of MDA in tumor tissue as compared with the Ehrlich solid tumor group [Figure 4].

3.4.2. Effect of ZnO-NPs on oxidative stress markers in liver tissue

No significant changes in oxidative stress parameter found in liver tissues in the ZnO NPs group [ZN] when compared to a liver of the control group. And also between [E + ZN] treated group when compared to [ZN] group. On the other hand, significant changes (p < 0.01) in oxidative stress parameter found in liver tissues in the [E + MTX] group compared to the liver of the control group. ZnO-NPs administration at the dose of 10 mg/kg does not affect liver oxidative stress parameters [Figure 4].
Figure 1: ZnO-NPs inhibits tumor growth in solid Ehrlich tumor. EAC cells were injected into Swiss albino mice (2×10^6 per mouse). After solid tumors grew to ~100 mm³, the mice were i.p. treated with or without ZnO-NPs (10 mg/kg/day). Inhibited tumor growth as measured by tumor volume. Solid tumors in the ZnO-NPs treated mice were significantly smaller than those in the MTX-treated mice.

Table 1: effect of ZnO-NPs on Bodyweight gain% in ESC-bearing mice, Tumor weight, volume, tumor-growth inhibition rate (TIR%), mean survival time (MST), and percent increase in life span (% ILS). Data are presented as mean ± SEM (ten animals /group ) *P<0.05, **P<0.01, and ***P<0.001 were set significant.

<table>
<thead>
<tr>
<th></th>
<th>Bodyweight gain %</th>
<th>Tumor weight (g)</th>
<th>Tumor volume (mm³)</th>
<th>TIR%</th>
<th>Survival time range (days)</th>
<th>MST (days)</th>
<th>ILS%</th>
<th>T/C%</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>- 10.84</td>
<td>1.31 ± 0.07</td>
<td>1655 ± 5.3</td>
<td>-----</td>
<td>31.25 - 40</td>
<td>35.62</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>E+ZN</td>
<td>37.11***</td>
<td>0.32 ± 0.09***</td>
<td>516 ±1.4***</td>
<td>68.8***</td>
<td>65 - 86***</td>
<td>75.5***</td>
<td>111.66***</td>
<td>211.66**</td>
</tr>
<tr>
<td>E+MTX</td>
<td>-13.35*</td>
<td>0.89 ± 0.11**</td>
<td>976 ± 3.1**</td>
<td>41.6**</td>
<td>45 - 65**</td>
<td>55.6**</td>
<td>55.3**</td>
<td>156.52**</td>
</tr>
</tbody>
</table>
Figure 2: Zinc Concentration in tumor/mammary gland and liver in studied groups. Highly significant*** (p<0.0001) increase in tumor treated with ZnO NPs [E + ZN].

Figure 3: Ethidium bromide-stained agarose gel showing patterns of the extracted DNA. M is the marker lane 50 bp Ladder. Each lane has four pooled DNA samples from each group. E(T), Ehrlich group (tumor tissue); E+ZN (L), Ehrlich group treated by ZnO-NPs (liver tissue); E + MTX(L), Ehrlich group treated by MTX (liver tissue) ; E + MTX(T), Ehrlich group treated by MTX (tumor tissue); E + ZN (T), Ehrlich group treated by ZnO-NPs (tumor tissue). The most severe pattern of DNA fragmentation was observed in ESC mice treated with ZnO-NPs.
Figure 4: Effect of ZnO-NPs on oxidative stress biomarkers (malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD) activities in tumor/mammary gland and liver homogenates in studied groups. Data are the mean ± SEM *P<0.05, **P<0.01, and ***P<0.001 were set significant.

4. Discussion

Zinc oxide nanoparticles (ZnO NPs) have received much attention for their implications in cancer therapy.[38] Studies have shown that ZnO NPs induce cytotoxicity in a cell-specific and proliferation-dependent manner, with rapidly dividing cancer cells being the most susceptible, and quiescent cells being the least sensitive.[16, 39] The present study reveals the effects of ZnO NPs on Ehrlich solid tumor and normal tissues (mammary gland and liver) and provides significant insight into the possible selective mechanism through which ZnO NPs exert their toxic effects on these cells. Our results demonstrate the cytotoxic potential of ZnO NPs in the Ehrlich solid tumor. Oxidative stress was found to be the underlying mechanism behind ZnO NPs induced DNA damage and cell death.

In our study, we evaluate the cytotoxic activity of ZnO NPs on carcinoma and normal cells. The mice inoculated with Ehrlich carcinoma showed a significant decrease in body weight gain compared to the treated ones. This result agrees with those obtained by Badr El-Din et al.[40] and Miranda-Vilela et al.[41] Reduction in body weight resulted in stunted growth not only due to reduced food consumption but also due to the tumor burden with its massive growth rate. Bodyweight gain shows a significant increase in ESC treated with ZnO NPs which demonstrates antitumor activity against Ehrlich solid tumor, as evidenced by marked suppression of tumor volume, weight, growth inhibition rate; moreover, the tumors appeared to grow slowly and their morphology was discontinuous and fragmented. This indicates that ZnO NPs exerted some inhibitory effects upon the
tumor cells. These findings may be attributed to reduced cell proliferation and/or increased apoptosis.

From another aspect, Zinc (Zn) distribution was measured in liver and Ehrlich tumor/mammary gland among groups. The mammary gland can resemble the normal control of Ehrlich solid, this type of Ehrlich tumor which appeared originally as a spontaneous breast carcinoma in a mouse can resemble breast cancer.[42] There was a significant difference in the distribution of Zn among the studied groups. The highest concentration of Zn in tumor tissues was recorded, although the liver was found to be the target organ of ZnO NPs.[43] High accumulation of zinc in tumor tissues proves that ZnO NPs were efficiently taken up by tumor tissues. ZnO NPs induce toxicity in a cell-specific and proliferation-dependent manner with rapidly dividing cells being the most susceptible and quiescent cells being the least sensitive. The marked difference in the cytotoxic response between cancer cells and their normal counterparts.[44] Hanley et al.[45] observed that there is an inverse relationship between nanoparticle size and cytotoxicity in mammalian cells, as well as nanoparticle size and reactive oxygen species production. Additionally, targeting tumor tissues occurs through the extravasations of nanoparticles post-injection into the systemic blood circulation. The biodistribution of these particles is dependent on the characteristics of blood capillaries in the organs and tissues as well as the administration site, particle size and particle surface properties.[46]

Zinc oxide nanoparticles induced a notable DNA fragmentation in form of laddering. The present work recorded that the electrophoresis pattern of DNA isolated from the untreated Ehrlich tumor group displayed an absence of DNA fragments. On the other hand, the electrophoresis pattern of DNA isolated from ESC treated with ZnO NPs group displayed ladder-like DNA fragmentation which is characteristic of DNA damage. The disappearance of DNA fragment bands postulates loss of apoptosis evident by the tumor development. Some types of tumors are characterized by defects in apoptosis leading to immortal clones of cells.[47] Most anticancer drugs have been known to cause DNA damage or suppress its replication, not necessarily killing the cells directly but inducing apoptosis.[48] When resolved using agarose gel electrophoresis, these DNA fragments appear as a nucleosomal ladder, a widely recognized hallmark of apoptosis. One of the key possible modes thought to be responsible for the toxic effects exerted by ZnO NPs via oxidative stress is DNA damage.[49] The generation of ROS has been attributed to their semiconductor and nanolevel characteristics which lead to ROS generation.[49-52] The electrons and holes can react with the oxygen and hydroxyl ions, respectively, present in the aqueous environment of ZnO NPs. This produces highly reactive free radicals including the superoxide anion radical (from electrons) and the hydroxyl radical (from holes).[53] Bai et al.[54] showed a higher level of zinc concentration, which suggests that the level of ROS was high and the redox balance was impaired, eventually leading to DNA fragmentation in human ovarian cancer cells. Our findings indicated that the ZnO NP-treated group showed a higher level of zinc concentration in the tumor, which suggests that the level of ROS was high and the redox balance was impaired, eventually leading to DNA fragmentation. Whereas ESC treated with ZnO NPs had started the apoptotic process, as was evident from DNA fragmentation analysis. Similarly, Akhtar et al.[55] reported that ZnO NP-treated human liver cancer HepG2 cells showed remarkable fragmentation of DNA.

With elevated levels of oxidative stress, ZnO NPs show a deleterious effect on the lipid, protein, and nucleic acid of the tumor tissues.[56] Elevated ROS can cause membrane damage through lipid peroxidation, protein denaturation, DNA damage, and cell death by apoptosis.[57] It has been suggested that oxidant generation and antioxidant depletion are the common pathways through which anticancer drugs trigger apoptosis in cancer cells.[58] Therefore, levels of MDA, GSH, along with the activities of antioxidant enzymes such as SOD and catalase in tumor and liver tissues were determined. The elevated level of MDA in ESC treated with ZnO NPs mice was observed in this study. The levels of the tri-peptide GSH and activity of antioxidant enzymes such as SOD and catalase were decreased after treatment with ZnO NPs. Depletion of GSH content for ZnO NPs was observed compared to controls suggesting that ZnO NPs is a potent ROS generator could be due to the increased generation of ROS and the excessive oxidative damage generated in mice. Xia et al.[59] reported that ZnO NPs induce generation of reactive oxygen species which can lead to cell death in A375 cells. When the antioxidative capacity of the cell is exceeded, Glutathione, a ubiquitous and abundant antioxidant cellular tripeptide, was found to be strongly depleted after exposure to ZnO NPs. Superoxide dismutase is specialized to convert the highly toxic superoxide radical to less toxic H$_2$O$_2$.[60] The catalase enzyme reduces H$_2$O$_2$ to H$_2$O$^\bullet\bullet$. More production of intracellular reactive oxygen species and more membrane lipid peroxidation in cells exposed to ZnO nanoparticles along with depletion of their antioxidant components suggest that oxidative stress might be a primary mechanism for the toxicity of ZnO NPs. These results agree with other studies which detected elevated levels of MDA in breast
cancer. The findings here are consistent with those of Abd El-Aziz et al. who noted that Ehrlich tumors exhibited significant increases in MDA and considerable decreases in catalase and SOD. MDA content manifests the level of lipid peroxidation and indirectly represents the level of damage to the tissue.

The GSH redox system is important for attenuating oxidative stress and in this process, GSH as a generalist radical scavenger is converted to oxidized glutathione (GSSG), while glutathione reductase continuously converts GSSG back to GSH. The malignant cells of different cancer types exhibit heterogeneity in the levels of oxidative stress associated with various expressive levels of SOD and other antioxidant enzymes. Decreased SOD activity in tumor tissues after treatment with ZnO NPs may be due to the increase in lipid peroxide. This can result in the accumulation of superoxide anions, a highly diffusible and potent oxidizing radical capable of traversing membranes causing deleterious effects. Throughout this experiment, the administration of ZnO NPs enhanced cytotoxicity by the generation of reactive oxygen species (ROS), leading to oxidative stress and eventually cell death.

CONCLUSION

By these studies, it was confirmed that ZnO NPs are safe and effective candidates to reduce the growth of cancer cells with no effect on normal cells according to nanoparticle size and concentration. Therefore, it is expected that ZnO NPs may be regarded as a new class of antitumorigenic and anticarcinogenic agents but we need more investigations and field applications.

5. References


49. Ng CT, Yong LQ, Hande MP, Ong CN, Yu LE, Bay BH, Baeg GH. Zinc oxide nanoparticles exhibit cytotoxicity and genotoxicity through oxidative stress responses in human lung fibroblasts and Drosophila melanogaster. International journal of nanomedicine 2017;12: 1621.


